Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trientine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.92 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 5/20 | 0.92 |
| ▸ | CA6 | P23280 | 5/20 | 0.92 |
| ▸ | CA7 | P43166 | 5/20 | 0.92 |
| ▸ | CA9 | Q16790 | 5/20 | 0.92 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.92 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.92 |
| ▸ | CA4 | P22748 | 4/20 | 0.92 |
| ▸ | CA5A | P35218 | 4/20 | 0.92 |
| ▸ | LMNA | P02545 | 3/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.92 |
| ▸ | CA3 | P07451 | 3/20 | 0.92 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.92 |
| ▸ | CA1 | P00915 | 2/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.92 |
| ▸ | TP53 | P04637 | 1/20 | 0.92 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | RECQL | P46063 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28797750 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL285388 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Trientine SCHEMBL506113 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL284758 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Trientine SCHEMBL2027642 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Trientine SCHEMBL205201 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Trientine SCHEMBL505712 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL1625351 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL1626082 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL28797761 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234532-B1 | TRIENTINE TETRAHYDROCHLORIDE AND A METHOD OF PREPARATION AND A PHARMACEUTICAL COMPOSITION THEREOF | YU JET CO LTD (TW) | 2026-05-20 | — | — | EP | claimed |
| US-20260027067-A1 | TRIENTINE LIQUID DOSAGE FORMS | BIOPHORE INDIA PHARMACEUTICALS PVT LTD (IN) | 2026-01-29 | — | — | US | claimed |
| EP-4565559-A1 | METHOD FOR TRIETHYLENETETRAMINE PURIFICATION | Philera New Zealand Ltd. (NZ) | 2025-06-11 | — | — | EP | claimed |
| US-12304881-B2 | Trientine tetrahydrochloride and a method of preparation and a pharmaceutical composition thereof | YU-JET CO., LTD (TW) | 2025-05-20 | — | — | US | claimed |
| CN-119968353-A | Triethylenetetramine purification process | 菲勒拉新西兰有限责任公司 | 2025-05-09 | — | — | CN | claimed |
| EP-4547232-A1 | TRIENTINE LIQUID DOSAGE FORMS | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2025-05-07 | — | — | EP | claimed |
| US-12281362-B2 | Diagnostic tools and treatments for clear cell renal cell carcinoma | UNIVERSITY OF CINCINNATI (US) | 2025-04-22 | — | — | US | claimed |
| US-20250114312-A1 | TREATMENT OF COPPER DISORDERS | PHILERA NEW ZEALAND LTD. (NZ) | 2025-04-10 | — | — | US | claimed |
| EP-4511013-A1 | TREATMENT OF BRAIN COPPER DISORDERS | Philera New Zealand Ltd. (NZ) | 2025-02-26 | — | — | EP | claimed |
| CN-119522094-A | Treatment of brain copper disorders | 菲勒拉新西兰有限责任公司 | 2025-02-25 | — | — | CN | claimed |
| US-20020098208-A1 | Method of treating aquatic animals with an antimicrobial agent and chelating agent | GEORGIA RESEARCH FOUNDATION, INC., THE UNIVERSITY | 2002-07-25 | — | — | US | claimed |
| US-20020091074-A1 | Medical compositions, dressings and methods for treating microbial infections of skin lesions | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., THE | 2002-07-11 | — | — | US | claimed |
| WO-2002048675-A2 | IMPROVED COMPOSITIONS AND METHODS FOR PRODUCING ANTIBODIES TO LOW MOLECULAR WEIGHT ANALYTES | TRANSDERM TECHNOLOGIES, LLC (US) | 2002-06-20 | — | — | WO | claimed |
| WO-2002024143-A2 | TREATING MICROBIAL INFECTION OF SKIN LESIONS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2002024201-A1 | METHOD OF TREATING AQUATIC ANIMALS WITH AN ANTIMICROBIAL AGENT AND CHELATING AGENT | UNIVERSITY OF GEORGIA (US) | 2002-03-28 | — | — | WO | claimed |
| EP-1169644-A1 | METHOD TO TYPE PRION PROTEINS | D-Gen Limited (GB) | 2002-01-09 | — | — | EP | claimed |
| EP-1115389-A1 | FRUCTOSAMINE OXIDASE: ANTAGONISTS AND INHIBITORS | Glycox Corporation Limited (NZ) | 2001-07-18 | — | — | EP | claimed |
| WO-2000062068-A1 | METHOD TO TYPE PRION PROTEINS | D-GEN LIMITED (GB) | 2000-10-19 | — | — | WO | claimed |
| WO-2000018392-A1 | FRUCTOSAMINE OXIDASE: ANTAGONISTS AND INHIBITORS | GLYCOX CORPORATION LIMITED (NZ) | 2000-04-06 | — | — | WO | claimed |
| US-5688516-A | Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-11-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027067-A1 | TRIENTINE LIQUID DOSAGE FORMS | SLC10A2, SLC10A1, SLC39A3 | CA2 1829/4885ESR1 3524/4885KDM4E 4645/4885 |
| US-12304881-B2 | Trientine tetrahydrochloride and a method of preparation and a pharmaceutical composition thereof | LIPC, SLC10A1, ADH1C | CA2 2205/4885ESR1 4804/4885KDM4E 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.